NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Aug 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETOPTIC is a selective beta-1 adrenergic receptor antagonist ophthalmic solution approved in 1985 for the treatment of elevated intraocular pressure and open-angle glaucoma. It reduces aqueous humor production in the eye, thereby lowering intraocular pressure and slowing disease progression. This small-molecule eye drop represents a foundational class of glaucoma therapy.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling a contracting team focused on margin protection and transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Started Jan 2019
366 enrolled
Primary Open-angle GlaucomaOcular Hypertension
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jan 2003
105 enrolled
GlaucomaOcular Hypertension
Career Relevance
BETOPTIC offers limited career growth potential given its approaching loss of exclusivity and mature market position. Professionals joining the team should expect focus on defensive strategies, cost management, and transition to newer assets rather than revenue expansion.
Worked on BETOPTIC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.